Group A Streptococcus Vaccine
Technology Platform: Infectious Disease
PREVENT, in collaboration with Vaxent, Inc. is developing a 30-valent vaccine which will provide coverage for at least 95% of North American and 90% of European GAS infections, as well as significant protection in the rest of the world. Phase I clinical study will be initiated in 2015.
- Group A streptococci (GAS) are ubiquitous human pathogens that cause a wide spectrum of clinical syndromes. Acute infections range from uncomplicated pharyngitis, cellulitis, and pyoderma to necrotizing fasciitis (flash-eating disease), sepsis, pneumonia, and streptococcal toxic shock syndrome. The non-suppurative sequelae that may follow GAS infections are acute rheumatic fever, rheumatic heart disease and post-streptococcal glomerulonephritis. Once initiated, these sequelae cannot be blocked with antibiotic treatment, making vaccination a highly desirable approach for PREVENT.
- The M proteins have been functionally defined as surface proteins that a) confer resistance to phagocytosis, and b) contain protective (opsonic) epitopes. The best evidence supports the use of multivalent, type-specific, M protein-based vaccines designed to elicit bactericidal antibodies against epidemiologically significant serotypes of group A streptococci.
- PREVENT is developing a 30-valent vaccine which will provide coverage for at least 95% of North American and 90% of European GAS infections, as well as significant protection in the rest of the world.
- GAS vaccine development is in collaboration with Vaxent Inc. Vaxent which is an early stage vaccine development company located in Memphis, Tennessee, whose lead product in development is a subunit vaccine against group A streptococcus which has been tested in early stage human clinical trials.
- Phase I clinical study initiation in 2015.